Chronic Hepatitis B (CHB) contributes to an increasing burden of liver disease. Between 15 – 40% of people with CHB in Australia will develop cirrhosis, liver failure and hepatocellular carcinoma (HCC). Patients with CHB require regular assessment and monitoring, a multi-disciplinary approach to patient management is essential to determine the appropriate treatment plan.

Serology Intepretation

Hepatitis B surface antigen (HbsAg) – active infection (acute or chronic)
Hepatitis B surface antibody (anti-HBs) – immunity or vaccinated
Hepatitis B core antibody (anti-HBc) – (infection past or current)

Ensure you request HBV serology on the pathology slip and indicate “?Chronic or Acute Hepatitis B Infection”, it is highly recommended to request the following tests to determine the phase of the disease:

• Hepatitis B surface antigen
• Hepatitis B core antibody
• Hepatitis B surface antibody
• HBeAg/anti-HBe status
• HBV DNA level